Detalhe da pesquisa
1.
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.
BMC Med;
21(1): 190, 2023 05 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37226224
2.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Clin Immunol;
169: 16-27, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27236001
3.
Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
J Immunol;
193(4): 1920-30, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25024381
4.
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
J Clin Immunol;
31(3): 443-54, 2011 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21174144
5.
CD14-independent responses induced by a synthetic lipid A mimetic.
Eur J Immunol;
40(3): 797-802, 2010 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20039305
6.
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
J Immunol;
183(10): 6186-97, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19864596
7.
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Vaccine;
33(8): 1084-91, 2015 Feb 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25444781
8.
Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.
Hum Vaccin Immunother;
10(3): 572-6, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24342916
9.
Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Expert Rev Vaccines;
10(4): 471-86, 2011 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21506645
10.
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
Expert Opin Biol Ther;
11(5): 667-77, 2011 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21457083
11.
The safety evaluation of adjuvants during vaccine development: the AS04 experience.
Vaccine;
29(27): 4453-9, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21527299
12.
Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
BioDrugs;
25(4): 217-26, 2011 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21815697
13.
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.
Vaccine;
29(13): 2461-73, 2011 Mar 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21256188
14.
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Vaccine;
28(3): 849-57, 2010 Jan 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19835828
15.
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vaccine;
26(10): 1375-86, 2008 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18272264
16.
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
Expert Rev Vaccines;
6(5): 723-39, 2007 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17931153
17.
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Vaccine;
24(33-34): 5937-49, 2006 Aug 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16828940